Buy Thymosin Alpha-1 (TA1) – Peptide Partners

Product Overview & Specifications

Thymosin Alpha-1 (TA1) is a naturally occurring thymic peptide investigated for its role in immune modulation, TLR signaling, phagocytosis enhancement, and cytokine regulation in preclinical research. Peptide Partners supplies this research-grade material for in-vitro testing, laboratory experimentation, receptor pharmacology, structural biology, and preclinical immunology research.

Published studies have examined TA1 using ex vivo patient blood cell analyses, human monocyte-derived macrophage (MDM) cultures, complement receptor phagocytosis assays, TLR signaling pathway profiling, CD4+/CD8+ T-cell subset characterization, cytokine expression profiling, and systematic clinical meta-analyses. Research areas include Toll-like receptor (TLR3, TLR4, TLR9) activation, IRF3 and NF-κB signaling, phagocytic activity enhancement, cytokine storm mitigation, T-cell exhaustion reversal, and immune homeostasis restoration.

The product name supplied for this listing is “Thymosin Alpha-1 (TA1).” Researchers should verify the exact identity, sequence, formulation, and batch-specific certificate of analysis before beginning any experiment. Findings from published TA1 studies should not be assumed to apply to every commercial batch or formulation.

Product Specifications

Specification	Details
Product name	Thymosin Alpha-1 (TA1)
Compound type	Naturally occurring thymic peptide (28 amino acids)
Primary molecular targets	Toll-like receptors (TLR3, TLR4, TLR9), complement receptors, IRF3, NF-κB
Primary research areas	Immune modulation, TLR signaling, phagocytosis enhancement, cytokine regulation, T-cell subset balance, cytokine storm mitigation, and inflammatory pathway modulation
Product format	10 mg vials
Vial size	10 mg
Vial capacity	3 mL
Available box combinations	20 mg, 50 mg, and 100 mg
Multi-vial purity	99.95%
Independent testing	Yes
Heavy-metals screening	Passed
Purity screening	Passed
Manufacturer ID	WF03
Batch ID	TA202602
Cost per milligram	$3.70–$4.90

The stated 99.95% purity is based on multi-vial testing. Researchers should review the batch-specific certificate of analysis before beginning any experiment.

Primary Research Studies & Findings

Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients

Authors: Claudia Matteucci, Antonella Minutolo, Emanuela Balestrieri, Vita Petrone, Marialaura Fanelli, Vincenzo Malagnino, Marco Ianetta, Alessandro Giovinazzo, Filippo Barreca, Silvia Di Cesare, Patrizia De Marco, Martino Tony Miele, Nicola Toschi, Antonio Mastino, Paola Sinibaldi Vallebona, Sergio Bernardini, Paola Rogliani, Loredana Sarmati, Massimo Andreoni, Sandro Grelli, and Enrico Garaci

Publication: Open Forum Infectious Diseases, 2021;8(1):ofaa588

PMCID: PMC7798699

Reference: View publication

Blood cells from patients with COVID-19 were analyzed to evaluate the biological processes regulated by thymosin alpha 1 (Tα1) under inflammatory conditions using ex vivo treatment and enrichment pathway analysis. Genes associated with cytokine signaling and production were found to be significantly upregulated in blood cells from COVID-19 patients, consistent with the characteristic cytokine storm observed in severe disease.

Ex vivo treatment with Tα1 mitigated cytokine gene expression and specifically inhibited lymphocyte activation in a CD8+ T-cell subset. The study demonstrated that Tα1 interacts with Toll-like receptor (TLR) signaling pathways, including TLR3, TLR4, and TLR9, activating downstream IRF3 and NF-κB signaling to modulate immune cell activity.

Tα1 was shown to restore homeostasis of the immune system by reversing T-cell exhaustion, reducing pro-inflammatory cytokine expression including interleukin-6 (IL-6), and modulating CD38 expression on CD8+ T cells in a manner dependent on disease severity. The findings support the potential role of Tα1 in controlling immune dysregulation and cytokine storm in SARS-CoV-2 infection in vivo.

Plain-English Research Summary

This research examined how TA-1, a peptide derived from the thymus gland, affects immune cells taken directly from COVID-19 patients. COVID-19 can trigger what’s called a cytokine storm — an out-of-control inflammatory response where immune cells flood the body with signaling chemicals that cause severe tissue damage. The researchers found that when they treated these patient blood cells with TA-1 in the laboratory, the peptide significantly dialed down the overactive immune response, particularly in a type of immune cell called CD8+ T cells. TA-1 essentially helped the immune system find its balance again rather than going into overdrive.

Thymosin α1 Activates Complement Receptor-Mediated Phagocytosis in Human Monocyte-Derived Macrophages

Authors: Annalucia Serafino, Fabrizio Pica, Francesca Andreola, Roberta Gaziano, Nadia Moroni, Gianluca Moroni, Manuela Zonfrillo, Pasquale Pierimarchi, Paola Sinibaldi-Vallebona, and Enrico Garaci

Publication: Journal of Innate Immunity, 2014;6(1):72–88

PMCID: PMC6741600

Reference: View publication

Human monocyte-derived macrophages (MDMs) were exposed to Tα1 in vitro to investigate its effects on innate immune cell activation and pathogen clearance. Tα1-treated MDMs assumed an activated morphology comparable to lipopolysaccharide (LPS)-treated cells but demonstrated a significantly greater ability to internalize fluorescent beads and zymosan particles.

Tα1 exposure stimulated MDM phagocytosis and killing of Aspergillus niger conidia in a dose-dependent manner, with effects observable as early as 30 minutes after challenge. The enhanced phagocytic activity occurred through a complement receptor-mediated mechanism, requiring intact microtubule network integrity and protein kinase C activity, with recruitment of vinculin and actin at the phagosome.

Crucially, this heightened phagocytic response was coupled with low transcription of pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6), indicating that Tα1 boosts pathogen clearance without triggering excessive inflammation. The findings demonstrate that Tα1 acts as a potent and early activator of innate immunity while maintaining an anti-inflammatory cytokine profile.

Plain-English Research Summary

This study looked at how TA-1 affects macrophages — the immune system’s front-line “cleanup crew” responsible for swallowing and destroying pathogens and cellular debris. The researchers found that treating macrophages with TA-1 dramatically increased their ability to engulf and kill fungal particles, with the effect kicking in within just 30 minutes. What makes this particularly notable is that TA-1 accomplished this without triggering the inflammatory chemical signals that normally accompany immune activation — the macrophages became more effective killers while simultaneously keeping inflammation low.

Thymosin Alpha 1 Alleviates Inflammation and Prevents Infection in Patients with Severe Acute Pancreatitis Through Immune Regulation: A Systematic Review and Meta-Analysis

Authors: Ye Tian, Jie Yao, Yulong Ma, Pengfei Zhang, Xinyi Zhou, Wenlong Xie, and Wei Tang

Publication: Frontiers in Immunology, 2025

DOI: 10.3389/fimmu.2025.1571456

Reference: View publication

A systematic review and meta-analysis was performed by searching PubMed, Embase, Web of Science, Cochrane Library, and the China National Knowledge Infrastructure (CNKI) through February 2025, identifying five randomized controlled trials comprising 706 patients with severe acute pancreatitis (SAP). Tα1 treatment significantly increased the percentage of CD4+ T cells (mean difference=4.53, 95% CI [3.02, 6.04], P<0.00001) and improved the CD4+/CD8+ ratio (mean difference=0.42, 95% CI [0.26, 0.58], P<0.00001), indicating restoration of immune cell balance.

Lower-dose Tα1 significantly reduced C-reactive protein (CRP) levels (mean difference=−30.12 mg/L, 95% CI [−35.75, −24.49], P<0.00001), a key marker of systemic inflammation. Tα1 treatment reduced the overall incidence of extrapancreatic infections by 44% (RR=0.56, 95% CI [0.40, 0.78], P=0.0005), with significant reductions in both bloodstream (RR=0.60) and abdominal (RR=0.38) infections.

Tα1 also significantly reduced APACHE II scores (mean difference=−1.52, 95% CI [−2.22, −0.83], P<0.0001), a standardized measure of illness severity. These results indicate that Tα1 can regulate immune cell balance, alleviate inflammatory burden, and reduce infectious complications in patients with severe systemic inflammation.

Plain-English Research Summary

This study pooled data from five separate clinical trials involving 706 patients with severe acute pancreatitis — a life-threatening condition where the pancreas begins attacking itself and triggers a dangerous full-body inflammatory response. The researchers found that patients treated with TA-1 showed meaningful improvements across several measures: their immune cell ratios normalized (indicating better immune balance), their blood levels of C-reactive protein — a standard marker doctors use to measure inflammation — dropped significantly, and their risk of developing dangerous secondary infections fell by nearly half. Patients also scored lower on a standardized medical severity scale, suggesting their overall condition improved more than those who didn’t receive TA-1.

Standard Research Disclaimer

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. It is designated exclusively for in-vitro testing and laboratory experimentation. All information provided about this product is educational and should be evaluated by appropriately qualified research personnel.

By law, bodily introduction of this product into humans or animals is strictly prohibited. This compound must not be used, administered, or represented as a drug, food, dietary supplement, immune treatment, COVID-19 treatment, pancreatitis treatment, infection prevention, diagnostic material, or medical treatment. It is not intended to diagnose, treat, cure, or prevent any disease. It should be handled only by licensed and qualified professionals in an appropriately equipped laboratory and in accordance with applicable laws, institutional procedures, and relevant safety requirements.